Attack Frequency Reduction
Emgality significantly reduced the number of weekly cluster headache attacks1
Emgality reduced the number of weekly cluster headache attacks by an average of 8.7 vs 5.2 with placebo over Weeks 1 to 31
ap=0.036 vs placebo.
SELECT IMPORTANT SAFETY INFORMATION
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
Mean change in weekly cluster headache attack frequency over Weeks 1 to 31
LS=least square; SE=standard error.